Warm Autoimmune Hemolytic Anemia: Clinical Profile and Management

Area of Science:

• Hematology
• Immunology
• Autoimmune Diseases

Background:

• Autoimmune hemolytic anemia (AIHA) is a rare autoimmune disorder.
• Warm antibody AIHA (wAIHA) constitutes 75-80% of adult AIHA cases.
• Corticosteroids are the primary treatment for wAIHA.

Purpose of the Study:

• To investigate the clinical profile and management of warm antibody autoimmune hemolytic anemia (wAIHA).
• To identify differences between primary and secondary wAIHA.
• To analyze treatment outcomes and patient demographics.

Main Methods:

• Retrospective analysis of 75 patients with wAIHA between January 2003 and January 2016.
• Data included patient demographics, clinical presentation, and treatment modalities.
• Statistical analysis to compare primary and secondary wAIHA groups.

Main Results:

• Significant differences observed in hemoglobin levels at onset between primary (7.1 ± 1.7 g/dL) and secondary (6.3 ± 1.2 g/dL) wAIHA.
• Splenectomy was significantly more common in secondary wAIHA (32.60%) compared to primary wAIHA (3.4%).
• Mean age of onset differed significantly between wAIHA secondary to lymphoma (69.7 ± 21.5 years) and other causes (54.3 ± 25.7 years).

Conclusions:

• Common causes of secondary wAIHA include B-cell lymphoma, SLE, RA, CLL, CVID, RCC, and certain drugs.
• Reducing corticosteroid cumulative dose and utilizing second-line treatments can mitigate risks of sepsis, particularly in elderly patients with comorbidities.
• Optimizing treatment strategies can reduce morbidity and mortality in wAIHA patients.